A carregar...
Chronic Myeloid Leukemia – Mechanisms of Resistance and Treatment
Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia (CML). Imatinib at a dose of 400 mg/day is considered the standard treatment for all newly diagnosed chronic phase CML. Follow-up on the pivotal International Randomized Study of I...
Na minha lista:
| Publicado no: | Hematol Oncol Clin North Am |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4428141/ https://ncbi.nlm.nih.gov/pubmed/22054730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hoc.2011.09.004 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|